Compare Moderna, Inc. (MRNA) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Walmart Stores Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 11.2× Moderna, Inc.'s market cap, and Walmart Stores Inc pays a 0.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Walmart Stores Inc for 101 Days on average.
| MRNA | WMT | |
|---|---|---|
Market Cap | $78.65B | $877.15B |
Volume | 37,373,437 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $225.00 | $134.20 |
52-Week Low | $22.36 | $100.61 |
Typical Hold Time | 59 Days | 101 Days |
Enterprise Value | $74.80B | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Walmart (WMT) trades at $110.56, up 2.27% with a bullish technical signal. The company demonstrates strong fundamentals with revenue reaching $680.99B in 2025 and consistent earnings beats. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships. The stock trades at a P/E of 40.06 and P/S of 1.2, reflecting premium valuation amid solid operational performance.
Walmart presents a compelling growth story with expanding digital services and market share gains. The primary investment opportunity lies in continued e-commerce momentum and operational efficiency. Key risks include valuation sensitivity, rising costs, and consumer spending pressures. Analyst consensus remains strongly bullish with a $128.84 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
